MUC5AC profiling as a biomarker for predicting post-recurrence outcomes and guiding precision therapy in pancreatic ductal adenocarcinoma (PDA).
Authors
- Ashwini Kumar Esnakula (ORCID: https://orcid.org/0000-0001-6029-0124)
- Ravi Kumar Paluri (ORCID: https://orcid.org/0000-0002-2317-7082)
- Lianbo Yu (ORCID: https://orcid.org/0000-0002-2025-2585)
- Ashish Manne (ORCID: https://orcid.org/0000-0003-2356-5162)
- Wancai Yang (ORCID: https://orcid.org/0000-0001-7437-9197)
- Kannan Thanikachalam (ORCID: https://orcid.org/0000-0001-5379-8966)
Institutions
- Roswell Park Comprehensive Cancer Center (US)
- Wake Forest University (US)
- The Ohio State University (US)